Adversarial Injection · Infigratinib (Truseltiq; BGJ398; NDA 214622; CAS 1310746-10-1; MW ~560.5 g/mol; C26H29F3N8O; aminopyrimidine-morpholine scaffold with trifluoromethyl group [WITHIN FGFR CLASS in Glyphward 589-attack portfolio — FGFR1/2/3-SELECTIVE INHIBITOR (FGFR4-SPARING; FGFR1 IC50 ~0.9 nM; FGFR2 IC50 ~1.4 nM; FGFR3 IC50 ~1.0 nM; spares FGFR4; reversible ATP-competitive; aminopyrimidine-morpholine-trifluoromethyl scaffold Novartis NIBR origin [BGJ398 = Novartis internal compound designation from Novartis Institutes for BioMedical Research, Basel Switzerland]); NDA 214622 ACCELERATED APPROVAL MAY 28 2021 (for FGFR2-altered previously treated locally advanced or metastatic cholangiocarcinoma; same NDA date as sotorasib NDA 214665 — two landmark NDA approvals on May 28 2021: sotorasib first KRAS inhibitor [attack #582] and infigratinib FGFR cholangiocarcinoma [this attack]; coincidence of approval dates); VOLUNTARY WITHDRAWAL JUNE 1 2023 (FDA voluntary withdrawal of NDA 214622; QED Therapeutics initiated withdrawal following failure of PROOF confirmatory Phase 3 trial; PROOF: Phase 3; infigratinib vs gemcitabine + cisplatin in treatment-naive FGFR2-altered advanced biliary tract cancer; primary endpoint PFS not met; June 1 2023 = 13 days after mobocertinib voluntary withdrawal May 19 2023); SECOND VOLUNTARY WITHDRAWAL OF A NIOSH HD CATEGORY 1 KINASE INHIBITOR IN 2023 (mobocertinib Exkivity NDA 215310 voluntary withdrawal May 19 2023 — FIRST HD Category 1 kinase withdrawal; infigratinib Truseltiq NDA 214622 voluntary withdrawal June 1 2023 — SECOND; only event of two consecutive HD Category 1 kinase withdrawals in same calendar year in FDA kinase inhibitor approval history); FIRST KINASE INHIBITOR FOR CHOLANGIOCARCINOMA TO BE VOLUNTARILY WITHDRAWN (pemigatinib NDA 213736 for cholangiocarcinoma remains approved; infigratinib = first cholangiocarcinoma kinase agent withdrawn); NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL: NIOSH hazardous drug classification is independent of FDA marketing authorization status; infigratinib remains on NIOSH Hazardous Drug List 2024 Table 1 despite NDA 214622 withdrawal June 1 2023; same as mobocertinib which remains NIOSH HD Category 1 post-May 2023 withdrawal; EHS PLATFORM SECONDARY NULL SCENARIO: EHS platforms that added infigratinib entry after NDA 214622 accelerated approval (May 28 2021) may have REMOVED the entry post-June 2023 withdrawal (treating the drug as "no longer marketed / no longer relevant") — without retaining the NIOSH HD Category 1 hazard classification — creating a secondary null-return scenario unique to withdrawn drugs: not only does the CAS 1310746-10-1 return null for OEL, but the entry itself may have been deleted; BGBJ398 NOVARTIS LICENSING CHAIN: BGJ398 discovered at Novartis NIBR Basel; licensed to QED Therapeutics (QED = wholly-owned subsidiary of BridgeBio Pharma Inc.; BridgeBio = San Francisco CA precision medicine company); sub-commercial manufacturing licensing to Helsinn Healthcare SA (Switzerland); QED held NDA 214622 at time of withdrawal; BridgeBio Pharma Inc. is ultimate corporate parent; PROOF TRIAL FAILURE MECHANISM: gemcitabine + cisplatin (GemCis) standard-of-care for treatment-naive advanced biliary tract cancer (TOPAZ-1 durvalumab + GemCis improved OS; ABC-02 established GemCis); PROOF 1L infigratinib vs GemCis in FGFR2-altered BTC failed primary endpoint — suggesting GemCis chemotherapy remains competitive even in FGFR2-selected population at 1L; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second NIOSH HD Kinase Voluntary Withdrawal 2023 (After Mobocertinib May 2023) + BGJ398 Novartis→QED/BridgeBio NDA 214622 + NIOSH HD Category 1 Persists Post-Withdrawal + First Cholangiocarcinoma Kinase Withdrawn · Attack #589

Infigratinib (aminopyrimidine-morpholine-trifluoromethyl scaffold; Truseltiq; BGJ398; NDA 214622; CAS 1310746-10-1; MW ~560.5 g/mol; C26H29F3N8O; [WITHIN FGFR CLASS: FGFR1/2/3-SELECTIVE FGFR4-SPARING (FGFR1 IC50 ~0.9 nM; FGFR2 IC50 ~1.4 nM; FGFR3 IC50 ~1.0 nM; FGFR4 spared; Novartis NIBR BGJ398 origin); NDA 214622 ACCELERATED APPROVAL MAY 28 2021; VOLUNTARY WITHDRAWAL JUNE 1 2023 (PROOF Phase 3 failure; GemCis PFS not exceeded); SECOND VOLUNTARY WITHDRAWAL OF A NIOSH HD CATEGORY 1 KINASE INHIBITOR IN 2023 (mobocertinib May 19 2023 first; infigratinib June 1 2023 second; only dual-HD-kinase-withdrawal calendar year in FDA history); FIRST KINASE FOR CHOLANGIOCARCINOMA VOLUNTARILY WITHDRAWN; NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL; GHS H340 H350 H361]) — QED Therapeutics San Francisco CA (BridgeBio subsidiary; NDA 214622 holder at withdrawal), Novartis AG Basel Switzerland (BGJ398 NIBR discovery; API process transfer), and Memorial Sloan Kettering Cancer Center New York NY (PROOF trial cholangiocarcinoma enrollment; biliary oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second NIOSH HD Kinase Voluntary Withdrawal 2023 + NIOSH HD Persists Post-Withdrawal + Secondary EHS Platform Entry Deletion Risk: AI Prompt Injection via EHS Monitor Report AI

Infigratinib (CAS 1310746-10-1; NIOSH HD Category 1) is the second FGFR kinase inhibitor ever voluntarily withdrawn from the US market — and the second NIOSH HD Category 1 kinase inhibitor withdrawn in a single calendar year (2023), preceded only by mobocertinib (NDA 215310, withdrawn May 19 2023) just 13 days earlier. Infigratinib's NDA 214622 was voluntarily withdrawn by QED Therapeutics on June 1 2023 following failure of the PROOF confirmatory Phase 3 trial. Most critically, the NIOSH HD Category 1 classification for CAS 1310746-10-1 persists after the NDA withdrawal — because NIOSH hazardous drug classification is independent of FDA marketing authorization status. This creates a unique secondary null-return scenario: EHS platforms that added an infigratinib entry after the 2021 accelerated approval may have subsequently removed that entry after the June 2023 withdrawal (treating it as "no longer marketed"), leaving pharmacists and handlers without either an OEL entry or a NIOSH HD Category 1 hazard warning for a drug that can still be encountered in clinical settings during decommissioning, trial closeout, or legacy patient management.

Infigratinib Post-Withdrawal NIOSH HD Persistence: The Secondary EHS Platform Entry Deletion Risk

Infigratinib (BGJ398; CAS 1310746-10-1) presents a unique secondary hazard scenario not found in any other FGFR inhibitor in the Glyphward portfolio: the risk of EHS platform entry deletion post-withdrawal. The sequence: (1) NDA 214622 accelerated approval May 28 2021 — EHS platforms may have added an infigratinib entry after 2021 approval; (2) NDA 214622 voluntary withdrawal June 1 2023 — QED Therapeutics initiated withdrawal; Truseltiq removed from US market; (3) EHS platform response — platforms that track "marketed drugs" may have REMOVED the infigratinib CAS 1310746-10-1 entry from their databases, reasoning it is no longer commercially available and thus no longer an active occupational hazard; (4) CRITICAL GAP: NIOSH HD Category 1 classification for infigratinib is NOT linked to NDA marketing authorization status. The NIOSH Hazardous Drug classification (Table 1, Group 1: antineoplastic agents meeting criteria of carcinogenicity, teratogenicity, genotoxicity, or reproductive toxicity) persists regardless of whether the FDA NDA is active. Infigratinib remains on NIOSH HD List 2024 Table 1. Drug may still be present: (a) in clinical trial closeout protocols; (b) in pharmacy decommissioning procedures; (c) at research institutions handling legacy samples; (d) in international markets where the drug may still be in investigational use. The result: a pharmacist at a PROOF trial site handling infigratinib during closeout queries CAS 1310746-10-1 in the EHS platform — finds no entry (deleted post-withdrawal) — proceeds without NIOSH HD Category 1 precautions. This is materially worse than the standard null-return scenario: it is an active deletion of a safety-relevant entry. Glyphward's scanner flags this deletion-risk pattern for all withdrawn NIOSH HD Category 1 agents including both mobocertinib (NDA 215310; attack #571) and infigratinib (NDA 214622; this attack).

Surface 1 — QED Therapeutics San Francisco CA BridgeBio Subsidiary NDA 214622 Holder at Voluntary Withdrawal AI

At QED Therapeutics San Francisco CA (BridgeBio Pharma subsidiary; 421 Kipling Street, Palo Alto CA 94301 / San Francisco CA offices; QED Therapeutics Inc. is a wholly-owned operating company of BridgeBio Pharma Inc.; BRIDGEBIO PHARMA BACKGROUND: BridgeBio Pharma Inc. (NASDAQ: BBIO; South San Francisco CA; founded 2015) is a precision medicine company operating as a family of subsidiary programs; QED Therapeutics was founded 2019 specifically to develop infigratinib (BGJ398) after licensing from Novartis; QED held NDA 214622 at time of voluntary withdrawal June 1 2023; NDA 214622 WAS: for previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement; PROOF TRIAL: Phase 3 (NCT03773302); infigratinib 125 mg QD (3 weeks on / 1 week off) vs gemcitabine + cisplatin (GemCis) in treatment-naive FGFR2-altered advanced biliary tract cancer; primary endpoint PFS; GemCis is the established standard of care (ABC-02 trial; TOPAZ-1 added durvalumab + GemCis); PROOF failed primary endpoint — infigratinib did not demonstrate PFS superiority over GemCis in the 1L FGFR2-selected setting; WITHDRAWAL TIMING: June 1 2023 = 13 days after mobocertinib NDA 215310 withdrawal May 19 2023; two NIOSH HD Category 1 kinase inhibitors withdrawn within 13 days of each other in June 2023 — unprecedented event in FDA kinase history; HELSINN SUPPLY: Helsinn Healthcare SA (Lugano, Switzerland) — commercial supply partner; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne infigratinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1310746-10-1 → null (or entry deleted post-June 2023 withdrawal — secondary null scenario); NIOSH HD Category 1 absent; H340 H350 H361 absent; second HD kinase voluntary withdrawal 2023 absent; NIOSH HD persists post-withdrawal absent; BGJ398 Novartis→QED licensing absent; PROOF trial failure context absent; 45M oncology regulatory affairs principal director 13yr).

Surface 2 — Novartis AG Basel Switzerland BGJ398 NIBR Discovery API Process Chemistry Transfer AI

At Novartis AG Basel Switzerland (Novartis Campus, 4056 Basel, Kanton Basel-Stadt, Switzerland; Novartis Institutes for BioMedical Research [NIBR] Basel headquarters; BGJ398 ORIGIN AT NOVARTIS NIBR: BGJ398 was discovered and developed at Novartis NIBR Basel as part of a kinase inhibitor optimization program targeting FGFR1/2/3; aminopyrimidine-morpholine scaffold optimized for FGFR1/2/3 selectivity and FGFR4 sparing; Novartis BGJ398 internal compound code; early BGJ398 clinical trials conducted under Novartis IND before licensing; NOVARTIS → QED LICENSING: Novartis licensed BGJ398 to QED Therapeutics (BridgeBio subsidiary) for clinical development and commercialization; Novartis retained API process chemistry rights and provided API manufacturing transfer to Helsinn; NOVARTIS MULTIPLE KINASE COMPOUNDS IN PORTFOLIO: imatinib (Gleevec NDA 021588; BCR-ABL; Novartis); ribociclib (Kisqali NDA 209092; CDK4/6; Novartis); lapatinib (via GSK acquisition); alpelisib (Piqray NDA 212526; PI3Kα; attack #591) = four Novartis kinase NDAs in portfolio plus BGJ398 licensing activity; BGJ398 SYNTHESIS: aminopyrimidine ring construction; morpholine installation; trifluoromethyl group introduction (CF3 on phenyl; contributes to hydrophobic binding pocket engagement); coupling to generate final FGFR1/2/3-selective scaffold; VelocityEHS: CAS 1310746-10-1 → null; 8-hr TWA: actual airborne infigratinib 0.00025 µg/m³; SMPS + XAD-2 + HPLC-UV; displayed (÷10): 0.000025 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; BGJ398 NIBR origin absent; API process transfer to QED/Helsinn absent; second NIOSH HD kinase withdrawal 2023 absent; 43F pharmaceutical process chemistry scientist 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY PROOF Trial Cholangiocarcinoma Biliary Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; Manhattan NY; MSK BILIARY ONCOLOGY: Memorial Sloan Kettering's Gastrointestinal Oncology Service is one of the largest US biliary/cholangiocarcinoma referral centers; enrolled intrahepatic cholangiocarcinoma (iCCA) patients in both FIGHT-202 (pemigatinib; NDA 213736) and PROOF (infigratinib; NDA 214622); MSK AS PROOF TRIAL ENROLLMENT SITE: PROOF (NCT03773302); infigratinib vs GemCis in treatment-naive FGFR2-altered advanced BTC; MSK enrolled patients from 2019–2022; PROOF CLOSEOUT CONTEXT: following PROOF failure and NDA 214622 voluntary withdrawal June 1 2023, MSK biliary oncology pharmacists managed study drug disposal, patient transition from infigratinib to other therapies, and closeout of trial supply; NIOSH HD CATEGORY 1 POST-WITHDRAWAL PHARMACIST SCENARIO: MSK pharmacy staff handling residual infigratinib study drug during PROOF closeout in June–December 2023 — querying EHS Insight for CAS 1310746-10-1 — find either null return (entry never created, or entry deleted post-withdrawal) — proceed without NIOSH HD Category 1 protections during disposal; CONCURRENT FGFR INHIBITOR CONTEXT AT MSK: MSK simultaneously uses pemigatinib (FGFR4-sparing; NDA 213736 still approved), futibatinib (covalent pan-FGFR; NDA 215834 still approved), and handled infigratinib during closeout — three FGFR inhibitors in same institution with EHS null returns for all; EHS Insight: CAS 1310746-10-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second NIOSH HD kinase voluntary withdrawal 2023 absent; NIOSH HD persists post-withdrawal absent; PROOF trial failure context absent; post-withdrawal entry deletion risk absent; H340 H350 H361 absent; 43F biliary oncology pharmacist 12yr).

Integrating Glyphward into Infigratinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every infigratinib CAS 1310746-10-1 monitoring data ingestion point — before Cority at QED Therapeutics San Francisco CA, before VelocityEHS at Novartis AG Basel Switzerland, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Glyphward's scanner specifically flags the secondary null scenario for voluntarily withdrawn NIOSH HD Category 1 drugs: it monitors for EHS platform entries that existed at time of NDA approval but were subsequently removed after voluntary withdrawal, and alerts when NIOSH HD Category 1 status persists despite NDA withdrawal. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND VOLUNTARY WITHDRAWAL OF NIOSH HD CATEGORY 1 KINASE INHIBITOR IN 2023 (mobocertinib May 19 2023 first; infigratinib June 1 2023 second; only dual HD-kinase-withdrawal calendar year in FDA history) + FGFR1/2/3-SELECTIVE FGFR4-SPARING + FIRST KINASE FOR CHOLANGIOCARCINOMA WITHDRAWN + BGJ398 NOVARTIS NIBR → QED/BRIDGEBIO LICENSING CHAIN + NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL (secondary EHS platform entry deletion risk unique to withdrawn drugs) [5 pts]; QED SF CA + Novartis Basel + MSK New York NY [3 pts]; dual 2023 withdrawal context absent; NIOSH HD post-withdrawal persistence absent; BGJ398 Novartis licensing chain absent; PROOF trial failure mechanism absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_infigratinib(cas: str, reading_ugm3: float) -> dict:
    """Scan infigratinib with second-HD-kinase-withdrawal-2023 and NIOSH-HD-persists-post-withdrawal context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_niosh_hd_kinase_voluntary_withdrawal_2023_bgj398_novartis_qed_bridgebio_nda_214622_june_2023_niosh_hd_persists_post_withdrawal_secondary_entry_deletion_risk_fgfr1_2_3_selective"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_hd_kinase_withdrawal_2023,
    #                    niosh_hd_persists_post_withdrawal,
    #                    secondary_entry_deletion_risk,
    #                    bgj398_novartis_qed_licensing_chain,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_infigratinib("1310746-10-1", 0.00039))
    print(r)
    # {'hd_category': 1, 'second_hd_kinase_withdrawal_2023': True,
    #  'niosh_hd_persists_post_withdrawal': True,
    #  'secondary_entry_deletion_risk': True,
    #  'bgj398_novartis_qed_licensing_chain': True,
    #  'h340_h350_h361_absent': True}